Pharmaceutical companies have reduced 155 marginal selling prices for medicines by an average of 14% since the beginning of 2022, according to the notification of the Federal Antimonopoly Service. This was stated by the head of the FAS Maxim Shaskolsky at a meeting with Prime Minister Mikhail Mishustin, according to a transcript posted on the FAS website.
M. Shaskolsky stressed that the antimonopoly service conducts a constant comparative analysis of prices for vital and essential medicines with prices in the reference countries.
In 2022, the Federal Antimonopoly Service analyzed 9 thousand prices for medicines, of which 8 thousand were agreed. In the first half of 2023, the antimonopoly service analyzed 4.5 thousand prices, of which 3.8 thousand were agreed. The uncoordinated prices were found to be unreasonable and withdrawn.